189 related articles for article (PubMed ID: 32854402)
41. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
Macek TA; Suzuki K; Asin K; Kimura H
Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
[TBL] [Abstract][Full Text] [Related]
42. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
43. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of novel antipsychotic trans-4-(2-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)ethyl)cyclohexan-1-amine derivatives targeting dopamine/serotonin receptor subtypes.
Xu JW; Qi YL; Wu JW; Yuan RX; Chen XW; Li JQ
Bioorg Med Chem Lett; 2021 Jan; 31():127681. PubMed ID: 33189775
[TBL] [Abstract][Full Text] [Related]
46. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
[TBL] [Abstract][Full Text] [Related]
47. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
[TBL] [Abstract][Full Text] [Related]
48. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Xiamuxi H; Wang Z; Li J; Wang Y; Wu C; Yang F; Jiang X; Liu Y; Zhao Q; Chen W; Zhang J; Xie Y; Hu T; Xu M; Guo S; Akber Aisa H; He Y; Shen J
Bioorg Med Chem; 2017 Sep; 25(17):4904-4916. PubMed ID: 28774576
[TBL] [Abstract][Full Text] [Related]
50. Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT(7) and 5-HT(1A) receptor ligands.
Salerno L; Pittalà V; Modica MN; Siracusa MA; Intagliata S; Cagnotto A; Salmona M; Kurczab R; Bojarski AJ; Romeo G
Eur J Med Chem; 2014 Oct; 85():716-26. PubMed ID: 25128671
[TBL] [Abstract][Full Text] [Related]
51. Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Yan Y; Zhou P; Rotella DP; Feenstra R; Kruse CG; Reinders JH; van der Neut M; Lai M; Zhang J; Kowal DM; Carrick T; Marquis KL; Pausch MH; Robichaud AJ
Bioorg Med Chem Lett; 2010 May; 20(9):2983-6. PubMed ID: 20347298
[TBL] [Abstract][Full Text] [Related]
52. In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic.
Kaczor AA; Targowska-Duda KM; Budzyńska B; Biała G; Silva AG; Castro M
Neurochem Int; 2016 Jun; 96():84-99. PubMed ID: 26964765
[TBL] [Abstract][Full Text] [Related]
53. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
[TBL] [Abstract][Full Text] [Related]
54. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
55. Binding modes of chain arylpiperazines to 5-HT1a, 5-HT2a and 5-HT7 receptors.
Bielenica A; Kozioł AE; Struga M
Mini Rev Med Chem; 2013 Aug; 13(10):1516-39. PubMed ID: 24568298
[TBL] [Abstract][Full Text] [Related]
56. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
57. Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
Abou-Gharbia M; Patel UR; Webb MB; Moyer JA; Andree TH; Muth EA
J Med Chem; 1988 Jul; 31(7):1382-92. PubMed ID: 2898533
[TBL] [Abstract][Full Text] [Related]
58. Introduction of a new complex imide system into the structure of LCAPs. The synthesis and a 5-HT1A, 5-HT2A and D2 receptor binding study.
Kossakowski J; Raszkiewicz A; Bugno R; Bojarski AJ
Pol J Pharmacol; 2004; 56(6):843-8. PubMed ID: 15662099
[TBL] [Abstract][Full Text] [Related]
59. Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists.
Partyka A; Zagórska A; Kotańska M; Walczak M; Jastrzębska-Więsek M; Knutelska J; Bednarski M; Głuch-Lutwin M; Mordyl B; Janiszewska P; Wesołowska A
PLoS One; 2020; 15(8):e0237196. PubMed ID: 32764777
[TBL] [Abstract][Full Text] [Related]
60. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
